12,077 Shares in Medpace Holdings, Inc. (NASDAQ:MEDP) Bought by Erste Asset Management GmbH

Erste Asset Management GmbH acquired a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 12,077 shares of the company’s stock, valued at approximately $4,022,000.

A number of other hedge funds have also added to or reduced their stakes in MEDP. Renaissance Technologies LLC increased its position in shares of Medpace by 38.3% during the second quarter. Renaissance Technologies LLC now owns 443,588 shares of the company’s stock valued at $182,692,000 after buying an additional 122,800 shares during the period. Clearbridge Investments LLC boosted its position in Medpace by 55.1% during the 2nd quarter. Clearbridge Investments LLC now owns 403,892 shares of the company’s stock valued at $166,343,000 after acquiring an additional 143,481 shares in the last quarter. Westwind Capital grew its holdings in shares of Medpace by 800.1% during the 2nd quarter. Westwind Capital now owns 380,929 shares of the company’s stock worth $156,886,000 after acquiring an additional 338,610 shares during the period. American Capital Management Inc. raised its position in shares of Medpace by 2.6% in the 3rd quarter. American Capital Management Inc. now owns 380,646 shares of the company’s stock worth $127,060,000 after acquiring an additional 9,592 shares in the last quarter. Finally, AQR Capital Management LLC raised its position in shares of Medpace by 62.3% in the 2nd quarter. AQR Capital Management LLC now owns 310,650 shares of the company’s stock worth $127,941,000 after acquiring an additional 119,257 shares in the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.

Medpace Trading Up 0.5 %

Medpace stock opened at $342.36 on Tuesday. Medpace Holdings, Inc. has a 12 month low of $273.14 and a 12 month high of $459.77. The stock has a fifty day simple moving average of $337.43 and a two-hundred day simple moving average of $370.62. The firm has a market cap of $10.64 billion, a price-to-earnings ratio of 29.98, a PEG ratio of 1.88 and a beta of 1.37.

Medpace (NASDAQ:MEDP) last issued its earnings results on Monday, October 21st. The company reported $3.01 earnings per share for the quarter, topping analysts’ consensus estimates of $2.77 by $0.24. The business had revenue of $533.32 million during the quarter, compared to analyst estimates of $540.99 million. Medpace had a return on equity of 50.87% and a net margin of 17.66%. Medpace’s revenue was up 8.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.22 EPS. On average, equities research analysts forecast that Medpace Holdings, Inc. will post 11.93 EPS for the current fiscal year.

Analysts Set New Price Targets

MEDP has been the topic of several recent research reports. William Blair reaffirmed an “outperform” rating on shares of Medpace in a research note on Tuesday, October 22nd. StockNews.com lowered shares of Medpace from a “buy” rating to a “hold” rating in a research note on Friday, September 27th. Baird R W lowered shares of Medpace from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 23rd. Redburn Atlantic assumed coverage on shares of Medpace in a research note on Monday, October 14th. They set a “buy” rating and a $404.00 target price for the company. Finally, Robert W. Baird upped their price target on Medpace from $349.00 to $354.00 and gave the stock a “neutral” rating in a research note on Monday, November 25th. Seven analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, Medpace presently has an average rating of “Hold” and a consensus target price of $380.56.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.